Literature DB >> 25991818

Spatiotemporal Heterogeneity Characterizes the Genetic Landscape of Pheochromocytoma and Defines Early Events in Tumorigenesis.

Joakim Crona1, Samuel Backman2, Rajani Maharjan2, Markus Mayrhofer3, Peter Stålberg2, Anders Isaksson3, Per Hellman2, Peyman Björklund2.   

Abstract

PURPOSE: Pheochromocytoma and paraganglioma (PPGL) patients display heterogeneity in the clinical presentation and underlying genetic cause. The degree of inter- and intratumor genetic heterogeneity has not yet been defined. EXPERIMENTAL
DESIGN: In PPGLs from 94 patients, we analyzed LOH, copy-number variations, and mutation status of SDHA, SDHB, SDHC, SDHD, SDHAF2, VHL, EPAS1, NF1, RET, TMEM127, MAX, and HRAS using high-density SNP array and targeted deep sequencing, respectively. Genetic heterogeneity was determined through (i) bioinformatics analysis of individual samples that estimated absolute purity and ploidy from SNP array data and (ii) comparison of paired tumor samples that allowed reconstruction of phylogenetic trees.
RESULTS: Mutations were found in 61% of the tumors and correlated with specific patterns of somatic copy-number aberrations (SCNA) and degree of nontumoral cell admixture. Intratumor genetic heterogeneity was observed in 74 of 136 samples using absolute bioinformatics estimations and in 22 of 24 patients by comparison of paired samples. In addition, a low genetic concordance was observed between paired primary tumors and distant metastases. This allowed for reconstructing the life history of individual tumors, identifying somatic mutations as well as copy-number loss of 3p and 11p (VHL subgroup), 1p (Cluster 2), and 17q (NF1 subgroup) as early events in PPGL tumorigenesis.
CONCLUSIONS: Genomic landscapes of PPGL are specific to mutation subtype and characterized by genetic heterogeneity both within and between tumor lesions of the same patient. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Year:  2015        PMID: 25991818     DOI: 10.1158/1078-0432.CCR-14-2854

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  13 in total

Review 1.  Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.

Authors:  P Björklund; K Pacak; J Crona
Journal:  J Intern Med       Date:  2016-05-10       Impact factor: 8.989

2.  Loss of BAP1 in Pheochromocytomas and Paragangliomas Seems Unrelated to Genetic Mutations.

Authors:  Valeria Maffeis; Rocco Cappellesso; Lorenzo Nicolè; Vincenza Guzzardo; Chiara Menin; Lisa Elefanti; Francesca Schiavi; Maria Guido; Ambrogio Fassina
Journal:  Endocr Pathol       Date:  2019-12       Impact factor: 3.943

Review 3.  New Perspectives on Pheochromocytoma and Paraganglioma: Toward a Molecular Classification.

Authors:  Joakim Crona; David Taïeb; Karel Pacak
Journal:  Endocr Rev       Date:  2017-12-01       Impact factor: 19.871

4.  PheoSeq: A Targeted Next-Generation Sequencing Assay for Pheochromocytoma and Paraganglioma Diagnostics.

Authors:  Maria Currás-Freixes; Elena Piñeiro-Yañez; Cristina Montero-Conde; María Apellániz-Ruiz; Bruna Calsina; Veronika Mancikova; Laura Remacha; Susan Richter; Tonino Ercolino; Natalie Rogowski-Lehmann; Timo Deutschbein; María Calatayud; Sonsoles Guadalix; Cristina Álvarez-Escolá; Cristina Lamas; Javier Aller; Julia Sastre-Marcos; Conxi Lázaro; Juan C Galofré; Ana Patiño-García; Amparo Meoro-Avilés; Judith Balmaña-Gelpi; Paz De Miguel-Novoa; Milagros Balbín; Xavier Matías-Guiu; Rocío Letón; Lucía Inglada-Pérez; Rafael Torres-Pérez; Juan M Roldán-Romero; Cristina Rodríguez-Antona; Stephanie M J Fliedner; Giuseppe Opocher; Karel Pacak; Esther Korpershoek; Ronald R de Krijger; Laurent Vroonen; Massimo Mannelli; Martin Fassnacht; Felix Beuschlein; Graeme Eisenhofer; Alberto Cascón; Fátima Al-Shahrour; Mercedes Robledo
Journal:  J Mol Diagn       Date:  2017-05-25       Impact factor: 5.568

Review 5.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

6.  Global DNA Methylation Analysis Identifies Two Discrete clusters of Pheochromocytoma with Distinct Genomic and Genetic Alterations.

Authors:  Samuel Backman; Rajani Maharjan; Alberto Falk-Delgado; Joakim Crona; Kenko Cupisti; Peter Stålberg; Per Hellman; Peyman Björklund
Journal:  Sci Rep       Date:  2017-03-22       Impact factor: 4.379

7.  Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients.

Authors:  Bruna Calsina; Maria Currás-Freixes; Alexandre Buffet; Tirso Pons; Laura Contreras; Rocío Letón; Iñaki Comino-Méndez; Laura Remacha; María Calatayud; Berta Obispo; Antoine Martin; Regis Cohen; Susan Richter; Judith Balmaña; Esther Korpershoek; Elena Rapizzi; Timo Deutschbein; Laurent Vroonen; Judith Favier; Ronald R de Krijger; Martin Fassnacht; Felix Beuschlein; Henri J Timmers; Graeme Eisenhofer; Massimo Mannelli; Karel Pacak; Jorgina Satrústegui; Cristina Rodríguez-Antona; Laurence Amar; Alberto Cascón; Nicole Dölker; Anne-Paule Gimenez-Roqueplo; Mercedes Robledo
Journal:  Genet Med       Date:  2018-07-16       Impact factor: 8.822

8.  Bioinformatic Challenges in Clinical Diagnostic Application of Targeted Next Generation Sequencing: Experience from Pheochromocytoma.

Authors:  Joakim Crona; Viktor Ljungström; Staffan Welin; Martin K Walz; Per Hellman; Peyman Björklund
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

9.  Multimodal Somatostatin Receptor Theranostics Using [(64)Cu]Cu-/[(177)Lu]Lu-DOTA-(Tyr(3))octreotate and AN-238 in a Mouse Pheochromocytoma Model.

Authors:  Martin Ullrich; Ralf Bergmann; Mirko Peitzsch; Erik F Zenker; Marc Cartellieri; Michael Bachmann; Monika Ehrhart-Bornstein; Norman L Block; Andrew V Schally; Graeme Eisenhofer; Stefan R Bornstein; Jens Pietzsch; Christian G Ziegler
Journal:  Theranostics       Date:  2016-03-10       Impact factor: 11.556

10.  Detecting Circulating Tumor DNA in Hepatocellular Carcinoma Patients Using Droplet Digital PCR Is Feasible and Reflects Intratumoral Heterogeneity.

Authors:  Ao Huang; Xin Zhang; Shao-Lai Zhou; Ya Cao; Xiao-Wu Huang; Jia Fan; Xin-Rong Yang; Jian Zhou
Journal:  J Cancer       Date:  2016-09-13       Impact factor: 4.207

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.